GBA1 and Gaucher disease: Ambroxol treatment also resulted in a significant elevation of glucosylceramidase activity levels (Fig. 6) and messenger RNA (Fig. 7) in Gaucher disease, Parkinson’s disease with GBA mutations and non-manifesting carriers.